BioSpace News Archive

C4 Therapeutics, Inc. today announced that it has entered into an exclusive license and collaboration agreement with Merck to develop degrader-antibody conjugates (DACs).

RedHill Biopharma Ltd. today announced that it received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).

Orthofix Medical Inc. announced the appointment of three new independent directors to the Company’s Board.

electroCore, Inc. today announced the United States Patent and Trademark Office has issued a patent related to a system for stimulating a nerve target in the head or neck of a patient for treatment of various disorders, such as primary headache.

Onconova Therapeutics, Inc. today announced preclinical data, highlighting narazaciclib’s preclinical activity in Bruton’s kinase inhibitor (BTKi)-resistant mantle cell lymphoma (MCL).

Viracta Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation to Nana-val (nanatinostat in combination with valganciclovir).

AstriVax is pleased to announce that it has been selected for funding by Flanders Innovation & Entrepreneurship.

CHARM Therapeutics today announced the promotion of Sarah Skerratt, Ph.D., to Chief Scientific Officer (CSO), and the appointment of Laura Hare as Chief People Officer and Head of Business Operations.

Pfizer Inc. (NYSE: PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer’s pending acquisition of Seagen Inc.

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, announced today positive results from 50 patients in two multi-center Phase 2 trials for UM171 cell therapy conducted at transplant centers in the U.S., Canada and Europe, building on prior strong data from a Phase 1/2 trial and comparative registry studies (CIBMTR and EBMT).